Contributions
Abstract: PB2283
Type: Publication Only
Background
Essential thrombocythemia (ET) is characterized by stem cell-derived clonal myeloproliferation with mutually exclusive "driver" mutations (JAK2, CALR, and MPL). Patients with ET have a high risk of thrombotic and hemorrhagic complications, and also a high risk of leukemic transformation. Increased levels of oxidative stress have been reported in patients with hematological disorders, including essential thrombocythemia. We previously reported that JAK2V617F-positive cases registered higher values of reactive oxygen species than healthy controls. Higher levels of oxidative stress markers have also been found in patients with essential thrombocythemia that also associated vascular events.1-9
Aims
To evaluate the antioxidant capacity in patients with ET and to observe if JAK2V617F-positive cases associate a lower antioxidant capacity and a higher risk for vascular events.
Methods
We evaluated 27 Romanian patients diagnosed with ET according to the 2016 revised WHO criteria. Informed consent was obtained from all patients enrolled. JAK2V617F mutation was detected by allele specific PCR testing. The antioxidant capacity was measured using a multidetection microplate reader FLUOstar Omega and a Sigma-Aldrich detection assay kit. Results were compared both to healthy controls and to each other. We compared the parameters of patients with ET and vascular events versus patients with ET and no vascular events. The exclusion criteria of this study were the presence of any condition associated with an increased oxidative stress status or the use of exogenous antioxidants. Statistical data analysis was performed using the student T-test (p-value ≤ 0.05 considered statistically significant).
Results
The study group involved 15 females and 12 males (median age = 54 years). Eight patients had vascular events: six patients had arterial or venous thrombosis (one of them associated thrombophilia) and two patients had hemorrhage. Fourteen patients were JAK2V617F-positive. All patients with vascular events were JAK2V617F-positive. All patients with ET had a lower antioxidant capacity compared to healthy controls (p≤ 0.05). The antioxidant capacity was significantly decreased in patients with ET and vascular events compared to patients with ET and no vascular events (p≤ 0.05). The patients with arterial thrombosis associated the presence of JAK2V617F, older age at diagnosis, leukocytosis, higher hemoglobin levels, and a lower antioxidant capacity (p≤ 0.05).
Conclusion
In our study group, ET patients had a lower antioxidant capacity than healthy controls. The history of vascular in ET patients was associated with a lower antioxidant capacity than ET patients with no previous vascular events or healthy controls. We may hypothesize that, via a decreased antioxidant capacity, oxidative stress is related to vascular events in ET in addition to the JAK2V617F status.
References: 1. Durmus A, et al. Med Princ Pract. 2014;23(3):253-8. 2. Marty C, et al. Leukemia. 2013 Nov;27(11):2187-95. 3. Bjørn ME, et al. Mediators Inflamm. 2015;2015:648090. 4. Gaman MA, et al. Haematologica. 2017; 102(s2):840. abstract n. PB2119. 5. Gaman AM, et al. Haematologica. 2015; 100(s1):772. abstract n. PB1967. 6. Gaman MA, et al. Haematologica. 2017; 102(s2):835. abstract n. PB2105. 7. Gaman AM, et al. Haematologica. 2014; 99(s1):773. abstract n. PB2030. 8. Gaman AM, et al. Aging Dis. 2016 May 27;7(3):307-17. doi: 10.14336/AD.2015.1022. 9. Gaman AM, et al. Oxid Med Cell Longev. 2014;2014:158135. doi: 10.1155/2014/158135.
Session topic: 16. Myeloproliferative neoplasms - Clinical
Keyword(s): Antioxidants, Essential Thrombocytemia, Mutation status, Reactive oxygen species
Abstract: PB2283
Type: Publication Only
Background
Essential thrombocythemia (ET) is characterized by stem cell-derived clonal myeloproliferation with mutually exclusive "driver" mutations (JAK2, CALR, and MPL). Patients with ET have a high risk of thrombotic and hemorrhagic complications, and also a high risk of leukemic transformation. Increased levels of oxidative stress have been reported in patients with hematological disorders, including essential thrombocythemia. We previously reported that JAK2V617F-positive cases registered higher values of reactive oxygen species than healthy controls. Higher levels of oxidative stress markers have also been found in patients with essential thrombocythemia that also associated vascular events.1-9
Aims
To evaluate the antioxidant capacity in patients with ET and to observe if JAK2V617F-positive cases associate a lower antioxidant capacity and a higher risk for vascular events.
Methods
We evaluated 27 Romanian patients diagnosed with ET according to the 2016 revised WHO criteria. Informed consent was obtained from all patients enrolled. JAK2V617F mutation was detected by allele specific PCR testing. The antioxidant capacity was measured using a multidetection microplate reader FLUOstar Omega and a Sigma-Aldrich detection assay kit. Results were compared both to healthy controls and to each other. We compared the parameters of patients with ET and vascular events versus patients with ET and no vascular events. The exclusion criteria of this study were the presence of any condition associated with an increased oxidative stress status or the use of exogenous antioxidants. Statistical data analysis was performed using the student T-test (p-value ≤ 0.05 considered statistically significant).
Results
The study group involved 15 females and 12 males (median age = 54 years). Eight patients had vascular events: six patients had arterial or venous thrombosis (one of them associated thrombophilia) and two patients had hemorrhage. Fourteen patients were JAK2V617F-positive. All patients with vascular events were JAK2V617F-positive. All patients with ET had a lower antioxidant capacity compared to healthy controls (p≤ 0.05). The antioxidant capacity was significantly decreased in patients with ET and vascular events compared to patients with ET and no vascular events (p≤ 0.05). The patients with arterial thrombosis associated the presence of JAK2V617F, older age at diagnosis, leukocytosis, higher hemoglobin levels, and a lower antioxidant capacity (p≤ 0.05).
Conclusion
In our study group, ET patients had a lower antioxidant capacity than healthy controls. The history of vascular in ET patients was associated with a lower antioxidant capacity than ET patients with no previous vascular events or healthy controls. We may hypothesize that, via a decreased antioxidant capacity, oxidative stress is related to vascular events in ET in addition to the JAK2V617F status.
References: 1. Durmus A, et al. Med Princ Pract. 2014;23(3):253-8. 2. Marty C, et al. Leukemia. 2013 Nov;27(11):2187-95. 3. Bjørn ME, et al. Mediators Inflamm. 2015;2015:648090. 4. Gaman MA, et al. Haematologica. 2017; 102(s2):840. abstract n. PB2119. 5. Gaman AM, et al. Haematologica. 2015; 100(s1):772. abstract n. PB1967. 6. Gaman MA, et al. Haematologica. 2017; 102(s2):835. abstract n. PB2105. 7. Gaman AM, et al. Haematologica. 2014; 99(s1):773. abstract n. PB2030. 8. Gaman AM, et al. Aging Dis. 2016 May 27;7(3):307-17. doi: 10.14336/AD.2015.1022. 9. Gaman AM, et al. Oxid Med Cell Longev. 2014;2014:158135. doi: 10.1155/2014/158135.
Session topic: 16. Myeloproliferative neoplasms - Clinical
Keyword(s): Antioxidants, Essential Thrombocytemia, Mutation status, Reactive oxygen species